April 23, 2018
TOKYO, JAPAN - April 23, 2018 - Vascutek and Bolton Medical, subsidiaries of Terumo Corporation of Japan, have combined into a single business as it looks to grow its presence in the global aortic and vascular implants market.
Known as Terumo Aortic, the integrated company will become a world leader in driving innovation and developing devices to treat aortic disease. As a combined business, Terumo Aortic aims to become recognised for its focus on individualised treatments that offer clinicians more options than ever before.
Terumo Aortic will have a combined revenue of nearly $200m and over 1,100 employees worldwide. Its primary research and manufacturing facilities will remain in Glasgow, Scotland and Sunrise, Florida.
The combined offering includes advanced technologies such as surgical grafts for abdominal, cardiothoracic and peripheral applications as well as hybrid and catheter-based stent graft systems for abdominal and thoracic aortic aneurysms. These implants have already helped to save or improve the lives of over two million patients in over 100 countries worldwide.
Vascutek and Bolton Medical have been working to consolidate and streamline their complementary offerings for the past year. Significant focus has been placed on creating an integrated research and innovation strategy that will push the boundaries of the aortic and vascular implants market.
Paul Holbrook, President of Terumo Aortic, said: "This coming together of two organisations with highly advanced technologies will be transformative for physicians and the patients they serve."
"We have woven together the products, services and expertise offered by our teams in Europe and the United States, enabling clinicians to meet the unique needs of their patients and redefine the treatment of aortic disease."
Terumo has combined Bolton Medical and Vascutek to power a dedicated approach focused on aortic innovation. With locations in Glasgow, Scotland and Sunrise, Florida, the integrated company offers advanced technologies such as surgical grafts, hybrid grafts and catheter-based stent graft systems to meet the unique needs of each patient and transform the treatment of aortic disease.
Corporate Communication Dept., Terumo Corporation
(Notice) Among the information that Terumo discloses, the forward-looking statements including financial projections are based upon our assumptions using information available to us at the time and are not intended to be guarantees of future events or performance. Accordingly, it should be noted that actual results may differ from those forecasts on projections due to various factors. Factors affecting to actual results include, but are not limited to, changes in economic conditions surrounding Terumo, fluctuations of foreign exchange rates, and state of competition. The market share information in this press release is partly derived from our own independent research.